Current Meeting     Our Mission     Future & Past Programs      Sponsorship     Board of Directors     Contact Us
Meeting Announcement
Register  Map
Date: Wednesday, January 21st, 2015
Topic: "Identification of Novel Immune Checkpoints as Targets for Cancer Immunotherapy "
Speaker: John Hunter, Ph.D
Vice President of Antibody R&D and Site Head
Compugen
Location:

The Holiday Inn
275 S Airport Blvd
South San Francisco, CA 94080
650-873-3550 | Map
Next door to the SSF Conference Center
Directions at www.hisfo.com

Price:

$50 before 9PM, Monday, December 15th
$60 on-site
$40 full-time students pre-registration
$50 full-time students on-site
$3 service fees will be added to the pre-registration prices

6:00 PM - networking
7:00 PM - dinner
8:00 PM - presentation

Abstract:

Members of the B7/CD28 family of immune checkpoints, such as CTLA4, PD1 and PDL-1, play critical roles in T cell regulation, and have emerged as exciting drug targets for cancer immunotherapy. Inhibition of these checkpoints can result in reactivation of patient immune response, reduction or disappearance of tumor burden, and long lasting remissions. While a subset of patients have dramatic responses to immune checkpoint inhibition, the majority of treated patients do not derive long term benefits from these drugs. A possible explanation is that there are additional undiscovered checkpoints affecting anti-tumor immune response. Utilizing a proprietary predictive discovery platform, we have identified 11 novel members of the B7/CD28 family that may serve as immune checkpoint targets for cancer therapy. A number of these have been validated for both expression and function, and are the basis of the therapeutic antibody development programs at Compugen

Biography:

John has worked for 18 years on different aspects of oncology drug development. Following graduate work at UCSF, John joined Millennium Pharmaceuticals, where he employed genomic approaches to identify novel drug targets in lung cancer. As a founding member of Millennium's Translational Medicine group he worked to develop clinical biomarkers for small molecule inhibitors of the Aurora kinase family. John later joined the Preclinical department at XOMA, managing early stage antibody discovery for multiple therapeutic programs in oncology and inflammation. He is currently the Site Head at Compugen USA Inc, where he leads therapeutic antibody research and development efforts for Compugen's portfolio of novel oncology targets.

Registration Policy    Registration via CEvent

Platinum Sponsors

Novartis
Pii

Gold Sponsors

Patheon
PPS
ChanTest
Deloitte
RHS Financial
MSL Group
SomaLogic
Pharmatek

Silver Sponsors

WAVSIP
Formurex
PerkinElmer
© BioSF.org ALL RIGHTS RESERVED BioScience Forum